Thiopurine S-methyltransferase genotype and the use of thiopurines in paediatric inflammatory bowel disease Greek patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 35, Issue 1, 2010, Pages 93-97

  Gazouli, M ^a   Pachoula, I ^b   Panayotou, I ^b   Mantzaris, G ^c   Syriopoulou, V P ^b   Goutas, N ^a   Vlachodimitropoulos, D ^a   Anagnou, N P ^a,d   Roma Giannikou, E ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d Academy of Athens Biomedical Research Foundation   (Greece)

Author keywords

6MP; Azathioprine; Inflammatory bowel disease; TPMT genotype

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE;

ADOLESCENT; ARTICLE; BONE MARROW APLASIA; CHILD; CROHN DISEASE; DRUG DOSE REDUCTION; DRUG INACTIVATION; DRUG METABOLISM; DRUG WITHDRAWAL; ENZYME POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENE MUTATION; GENOTYPE; GREECE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PANCREATITIS; PRESCHOOL CHILD; SCHOOL CHILD; TPMT GENE; ULCERATIVE COLITIS;

6-MERCAPTOPURINE; ADOLESCENT; ALLELES; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC ASSOCIATION STUDIES; GREECE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 74349127741     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2009.01041.x     Document Type: Article

References (20)

1. Fuentes D, Torrente F, Keady S et al. (2003) High-dose azathioprine in children with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 177, 913 921.
2. Barabino A, Torrente F, Ventura A et al. (2002) Azathioprine in paediatric inflammatory bowel disease: an Italian multicentre survey. Alimentary Pharmacology and Therapeutics, 16, 1125 1130. (Pubitemid 34680755)
3. Fraser AG, Orchard TR, Jewell DP (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut, 50, 485 489.
4. Cuffari C, Hunt S, Bayless T (2001) Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut, 48, 642 646.
5. Schaeffeler E, Eichelbaum M, Reinisch W, Zanger UM, Schwab M (2006) Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Human Mutation, 27, 976.
6. McLeod HL, Siva C (2002) The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics, 3, 89 98.
7. Gearry RB, Barclay ML, Burt MJ et al. (2003) Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 18, 395 400.
8. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM (1991) Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukaemia. Journal of Pediatrics, 119, 985 989.
9. Evans WE, Hon YY, Bomgaars L et al. (2001) Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. Journal of Clinical Oncology, 19, 2293 2301.
10. Evans WE (2004) Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Therapeutic Drug Monitoring, 26, 186 191.
11. Aberra FN, Lichtenstein GR (2005) Review article: monitoring of immunomodulators in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 21, 307 319.
12. Lennard-Jones JE (1989) Classification of inflammatory bowel disease. Scandinavian Journal of Gastroenterology Supplement, 170, 2 6.
13. Hiratsuka M, Inoue T, Omori F, Agatsuma Y, Mizugaki M (2000) Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutation Research, 448, 91 95.
14. Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR (2005) Thiopurines in inflammatory bowel disease: pharmacogenetics, theurapeutic drug monitoring and clinical recommendations. Digestive Liver Disease, 37, 282 297.
15. Sanderson J, Ansari A, Marinaki T, Duley J (2004) Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy? Annals of Clinical Biochemistry, 41, 294 302.
16. Kirschenr BS (1998) Safety of azathioprine and 6-mercaptopurine in paediatric patients with inflammatory bowel disease. Gastroenterology, 115, 813 821.
17. Stocco G, Martelossi S, Barabino A et al. (2005) TPMT genotype and the use of thiopurine in paediatric inflammatory bowel disease. Digestive Liver Disease, 37, 940 945.
18. Schwab M, Schäffeler E, Marx C et al. (2002) Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics, 12, 429 436.
19. De Ridder L, Van Dieren JM, Van Deventer HJ et al. (2006) Pharmacogenetics of thiopurine therapy in paediatric IBD patients. Alimentary Pharmacology and Therapeutics, 23, 1137 1141.
20. Fakhoury M, Gallien-Andreu J, Mahr A et al. (2007) Should TPMT genotype and activity be used to monito 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia? Journal of Clinical Pharmacy Therapeutics, 32, 633 639.